News

News

Read our latest news below, or sign up for our annual newsletter to keep up to date.

What we can learn about autism in adults from the eye?

In a recent study, AIMS-2-TRIALS researchers focused on a response of the retina in the eyes, which relies on a chemical messenger, known as neurotransmitter, to regulate communication between nerve cells (neurons). The neurotransmitter of interest is γ-Aminobutyric...

read more
Autism Without Boarders Award Event 2023

Autism Without Boarders Award Event 2023

Both Artist and Researcher Celebrated at the 2023 ‘AUTISM WITHOUT BOARDERS’ Award Event In 2023, the ‘AUTISM WITHOUT BOARDERS’ Award was held at the Institute for Research Hospitalization and Health Care (IRCCS) in Pisa, Italy in November 2023. This Award was...

read more
Art & Science Competition and Exhibition

Art & Science Competition and Exhibition

To raise awareness about autism, challenge misconceptions, and promote neurodiversity, members of the Cambridge study team working on AIMS-2-TRIALS collaborated with a group of six autistic people and parents of autistic people (A-Reps) to design a creative project...

read more
AIMS-2-TRIALS is in the ‘Top 10’ IMI Projects

AIMS-2-TRIALS is in the ‘Top 10’ IMI Projects

A recent report published by the Innovative Medicines Initiative (IMI), the world’s largest public-private partnership in the life sciences, showed that AIMS-2-TRIALS have published the most papers out of all Phase 2 IMI-funded projects. Since the IMI was launched,...

read more
New Project: European Autism Genomics Registry

New Project: European Autism Genomics Registry

The genetics of autism are very complex. Some autistic people have a genetic syndrome associated with autism, like Angelman syndrome or dup15q syndrome, whilst others do not. Given the diversity of autism, it is important that research looks at the broad range of...

read more
AIMS-2-TRIALS consultation on data sharing

AIMS-2-TRIALS consultation on data sharing

Sharing scientific research data is important because it can help improve the quality, usefulness, and reliability of research. For example, it enables scientists to analyse larger data sets, which increases their ability to uncover patterns in the data. Data sharing...

read more
Recognising faces: microstates

Recognising faces: microstates

AIMS-2-TRIALS researchers have been exploring how people process faces, both in autistic and non-autistic individuals. Previous research has shown that most people find it trickier to recognise upside down (inverted) faces compared to upright faces (see image on the...

read more
AIMS-2-TRIALS Work Package Updates for 2022

AIMS-2-TRIALS Work Package Updates for 2022

Research studies across the lifespan Project updates:  Over the past year, recruitment of participants and families to our AIMS-2-TRIALS cohort studies has grown at its most significant rate since pandemic-related restrictions on face-to-face research eased. The Leads...

read more
The Value of Treatment

The Value of Treatment

Find out about the outcome of our research projects looking at care pathways for autism and autism with co-occurring epilepsy, including data from the UK, Spain and Italy. We explore treatment gaps/unmet needs, screening and diagnosis times, funding and make...

read more
AIMS-2-TRIALS Partners involved in Lancet Commission

AIMS-2-TRIALS Partners involved in Lancet Commission

The Lancet has launched a first-of-its-kind Commission that “aims to answer the question of what can be done in the next 5 years to address the current needs of autistic individuals and families worldwide.” The Commission’s 32 representatives are co-led by Prof Tony...

read more